StockMirror — Stock Screener

AUROPHARMA Q2 FY27 Results & Earnings Analysis

Sentiment: Good (Confidence: high)

Earnings Summary

Aurobindo Pharma delivered its highest-ever quarterly revenue of ₹10,263 crores (+24% YoY) with operating EBITDA of ₹2,156 crores (+28% YoY) at 21% margin despite input cost and freight headwinds. Growth was broad-based across US (+25% YoY, $477M), Europe (+18% cc, €288M), API (+21% YoY), and Growth Markets (+16% YoY). Gross margin expanded 150 bps YoY to 61.2%. The company completed the Lannett acquisition, acquired A1 Biochem for CRDMO, launched ADQUEY (first NDA) and generic Advair, and received VAI classification for Raleigh. Net cash position of $189M with strong quarterly cash flow of $146M. FY27 guidance reiterated: double-digit revenue growth, EBITDA margins >21%, absolute EBITDA >₹8,000 crores. FY28 expected to be 'far better than FY27' with 22%+ EBITDA margins. Key monitorables: Lannett integration and utilization, China facility breakeven, respiratory pipeline progress, biosimilar strategy execution, and Pen-G PLI benefits.

Management Tone

Revenue Growth Drivers

Growth vs Margin Focus

Management emphasizes balanced approach with focus on sustainable growth, product mix improvement, manufacturing efficiencies, and margin expansion. FY27 guidance includes double-digit revenue growth AND EBITDA margins north of 21% with absolute EBITDA >₹8,000 crores. FY28 targets 22%+ EBITDA margin

About Aurobindo Pharma Limited

Aurobindo Pharma Limited (AUROPHARMA) is listed on NSE. View the latest earnings analysis, AI-powered insights, and sentiment data on StockMirror.

Explore More